NYVEPRIA 6 mg INJECTABLE SOLUTION

Introduction

Package Leaflet: Information for the User

Nyvepria 6 mg Solution for Injection

pegfilgrastim

This medicine is subject to additional monitoring, which will allow for quick identification of new safety information. You can help by reporting any side effects you may get. The last section of this leaflet includes information on how to report side effects.

Read all of this leaflet carefully before you start using this medicine because it contains important information for you.

• Keep this leaflet, you may need to read it again.
• If you have any further questions, ask your doctor, pharmacist, or nurse.
• This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours.
• If you get any side effects, talk to your doctor, pharmacist, or nurse. This includes any possible side effects not listed in this leaflet. See section 4.

Contents of the Package Leaflet

1. What is Nyvepria and what is it used for
2. What you need to know before you use Nyvepria
3. How to use Nyvepria
4. Possible side effects
5. Storage of Nyvepria
6. Contents of the pack and other information

1. What is Nyvepria and what is it used for

Nyvepria contains the active substance pegfilgrastim. Nyvepria is used in patients treated with cytotoxic chemotherapy (medicines that destroy rapidly dividing cells) to reduce the duration of neutropenia (low count of neutrophils, a type of white blood cell) and to help prevent febrile neutropenia (low count of white blood cells with fever). Nyvepria is indicated in patients aged 18 years and older.

White blood cells are important for fighting infections. If the white blood cell count becomes too low due to cytotoxic chemotherapy, your body may not be able to fight off microorganisms, which can increase the risk of infection. Pegfilgrastim is very similar to a natural protein in the body called granulocyte-colony stimulating factor and works by stimulating your bone marrow to produce more white blood cells to help fight infections.

2. What you need to know before you use Nyvepria

Do not use Nyvepria

• if you are allergic to pegfilgrastim, filgrastim, or any of the other ingredients of this medicine (listed in section 6).

Warnings and Precautions

Consult your doctor, pharmacist, or nurse before using Nyvepria:

• if you have recently had a severe lung infection (pneumonia), fluid in the lungs (pulmonary edema), inflammation of the lungs (interstitial lung disease), or an abnormal chest X-ray result (pulmonary infiltrate).
• if you are aware of any changes in your blood cell count (e.g., increased white blood cell count or anemia) or a decrease in your blood platelet count (thrombocytopenia), which can reduce the ability of your blood to clot. Your doctor may want to monitor you more closely.
• if you have sickle cell anemia. Your doctor may monitor your condition more closely.

Consult your doctor, pharmacist, or nurse while using Nyvepria:

• if you are a cancer patient with breast cancer or lung cancer, the combined treatment of pegfilgrastim with chemotherapy and/or radiotherapy may increase the risk of developing a pre-cancerous blood disorder called myelodysplastic syndrome (MDS) or a blood cancer called acute myeloid leukemia (AML). Symptoms may include fatigue, fever, easy bruising or bleeding.

• if you have an allergic reaction that includes weakness, low blood pressure, difficulty breathing, swelling of the face, lips, tongue, or other parts of the body (anaphylaxis), flushing, and skin rash with itching.
• if you experience cough, fever, and difficulty breathing. This may be a sign of acute respiratory distress syndrome (ARDS).
• if you experience any of the following side effects:
  • inflammation or swelling, decreased urination, difficulty breathing, abdominal swelling and feeling of fullness, and general feeling of tiredness.

These may be symptoms of a condition called "capillary leak syndrome" that can cause blood to leak from small blood vessels into other parts of your body. See section 4.

• if you have pain in the upper left abdomen or pain in the left shoulder tip. This may be a sign of a problem with your spleen (splenomegaly).
• if you have fever, abdominal pain, general discomfort, and back pain, as these may be symptoms of inflammation of the aorta (the large blood vessel that carries blood from the heart to the rest of the body). This condition can occur rarely in cancer patients and healthy donors.

Your doctor will perform regular blood and urine tests since Nyvepria may harm your kidneys (glomerulonephritis).

With the use of pegfilgrastim, serious skin reactions (Stevens-Johnson syndrome; a condition that causes painful blisters and ulcers on the skin and mucous membranes, especially in the mouth) have been reported. Stop using Nyvepria and seek medical attention immediately if you notice any of these symptoms: red, often circular, patches on the trunk, exfoliation, ulcers in the mouth, throat, nose, genitals, and eyes, possibly with fever and flu-like symptoms beforehand. See section 4.

You should discuss with your doctor the risk of developing blood cancer. If you have blood cancer or your doctor has told you that you are at risk of developing it, you should not use Nyvepria, unless your doctor advises you to.

Loss of Response to Pegfilgrastim

If treatment with pegfilgrastim does not work or stops working, your doctor will investigate the reason, including whether you have developed antibodies that may neutralize the activity of pegfilgrastim.

Children and Adolescents

Nyvepria is not recommended for use in children and adolescents because there is not enough information on its safety and effectiveness.

Other Medicines and Nyvepria

Tell your doctor or pharmacist if you are using, have recently used, or might use any other medicines.

Pregnancy and Breastfeeding

If you are pregnant or breastfeeding, think you may be pregnant, or are planning to have a baby, ask your doctor or pharmacist for advice before using this medicine.

Nyvepria has not been studied in pregnant women. Therefore, your doctor may decide that you should not use this medicine.

If you become pregnant during treatment with Nyvepria, inform your doctor.

Unless your doctor tells you otherwise, you must stop breastfeeding if you use Nyvepria.

Driving and Using Machines

Nyvepria has no or negligible influence on the ability to drive and use machines.

Nyvepria Contains Sorbitol (E420) and Sodium

This medicine contains 30 mg of sorbitol in each pre-filled syringe, equivalent to 50 mg/ml. The cumulative effects of administration with other medicines containing sorbitol (or fructose) and dietary intake of sorbitol (or fructose) should be taken into account.

This medicine contains less than 23 mg of sodium (1 mmol) per 6 mg dose; this is essentially "sodium-free".

3. How to Use Nyvepria

Nyvepria is indicated in patients aged 18 years and older.

Follow the instructions for administration of this medicine exactly as told by your doctor. If you are unsure, consult your doctor or pharmacist again.

The recommended dose is a single subcutaneous injection of 6 mg (under the skin) using a pre-filled syringe, which should be administered at the end of each chemotherapy cycle, at least 24 hours after your last dose of chemotherapy.

Self-Administration of Nyvepria

Your doctor may consider that you can inject Nyvepria yourself. Your doctor or nurse will teach you how to do it. Do not attempt to do it if you have not been taught.

For instructions on how to inject Nyvepria yourself, read the section 6 at the end of this leaflet.

Do not shake Nyvepria vigorously, as this may affect its activity.

If You Use More Nyvepria Than You Should

If you use more Nyvepria than you should, consult your doctor, pharmacist, or nurse.

If You Forget to Use Nyvepria

If you have missed your dose of Nyvepria, contact your doctor to decide when you should have your next injection.

If you have any further questions on the use of this medicine, ask your doctor, pharmacist, or nurse.

4. Possible Side Effects

Like all medicines, this medicine can cause side effects, although not everybody gets them.

Tell your doctor immediately if you experience any of the following side effects:

• inflammation or swelling, decreased urination, difficulty breathing, abdominal swelling and feeling of fullness, and general feeling of tiredness. These symptoms usually develop rapidly.

These may be symptoms of a condition called "capillary leak syndrome" that can cause blood to leak from small blood vessels into other parts of your body and may require urgent treatment.

Very Common: may affect more than 1 in 10 people

• bone pain. Your doctor will inform you about what you can take to relieve the pain.
• nausea and headache.

Common: may affect up to 1 in 10 people

• injection site pain.
• general pain and pain in the joints and muscles.
• some changes in your blood may occur, which will be detected by regular blood tests. The number of white blood cells may increase for a short period. The number of platelets may decrease, which can cause bruising.
• chest pain not related to heart problems.

Uncommon: may affect up to 1 in 100 people

• allergic reactions, including flushing, rash, and itching.
• severe allergic reactions, including anaphylaxis (weakness, low blood pressure, difficulty breathing, swelling of the face).
• increase in the size of the spleen (the spleen is an organ located in the abdomen to the left of the stomach that is involved in the production and removal of blood cells and is part of the immune system). Tell your doctor if you experience an increase in size in the upper left part of your abdomen.
• rupture of the spleen, which can be fatal. It is important that you contact your doctor immediately if you have pain in the upper left part of your abdomen or in the left shoulder tip, as these may be related to a problem with your spleen.
• respiratory problems. If you have cough, fever, and difficulty breathing, consult your doctor.
• cases of Sweet's syndrome (painful, inflamed, purple-colored lesions on the limbs and sometimes on the face and neck, accompanied by fever) have been reported.
• cutaneous vasculitis (inflammation of the blood vessels in the skin).
• kidney damage (glomerulonephritis).
• redness at the injection site.
• bleeding from the lungs (hemoptysis).
• hematological disorders (myelodysplastic syndrome [MDS] or acute myeloid leukemia [AML]).

Rare: may affect up to 1 in 1,000 people

• inflammation of the aorta (the blood vessel that carries blood from the heart to the rest of the body), see section 2.
• bleeding from the lungs (pulmonary hemorrhage).
• Stevens-Johnson syndrome, which may appear as red, often circular, patches on the trunk, exfoliation, ulcers in the mouth, throat, nose, genitals, and eyes, possibly with fever and flu-like symptoms beforehand. Stop using Nyvepria and seek medical attention immediately if you develop these symptoms. See section 2.

Reporting of Side Effects

If you experience any side effects, talk to your doctor, pharmacist, or nurse, even if they are not listed in this leaflet. You can also report side effects directly via the national reporting system listed in Appendix V. By reporting side effects, you can help provide more information on the safety of this medicine.

5. Storage of Nyvepria

Keep this medicine out of the sight and reach of children.

Do not use this medicine after the expiry date which is stated on the carton and on the label of the pre-filled syringe after EXP. The expiry date refers to the last day of the month shown.

Store in a refrigerator (2°C - 8°C).

Nyvepria may be stored at room temperature (below 25°C) for a maximum of 15 days. Once a pre-filled syringe has been removed from the refrigerator and reaches room temperature (below 25°C), it must be used within 15 days or discarded.

Do not freeze. Nyvepria can be used after accidental freezing for a period of less than 24 hours.

Keep the container in the outer carton to protect from light.

Do not use this medicine if you notice that the solution is not entirely clear or contains particles.

Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. These measures will help protect the environment.

6. Container Contents and Additional Information

Composition of Nyvepria

• The active substance is pegfilgrastim. Each pre-filled syringe contains 6 mg of pegfilgrastim in 0.6 ml of solution.
• The other ingredients are sodium acetate trihydrate, glacial acetic acid, sorbitol (E420), polysorbate 20, and water for injectable preparations (see section 2 "Nyvepria contains sorbitol (E420) and sodium acetate").

Appearance and Container Contents of the Product

Nyvepria is a clear, colorless, and particle-free injectable solution in a pre-filled syringe (6 mg/0.6 ml).

Each pack contains 1 pre-filled glass syringe with a stainless steel needle, a needle cap, and an automatic needle guard.

Marketing Authorization Holder

Pfizer Europe MA EEIG

Boulevard de la Plaine 17

1050 Bruxelles

Belgium

Manufacturer

Hospira Zagreb d.o.o.

Prudnicka cesta 60

10291 Prigorje Brdovecko

Croatia

You can request more information about this medicine by contacting the local representative of the marketing authorization holder.

Date of Last Revision of this Leaflet:

Other Sources of Information

Detailed information on this medicinal product is available on the European Medicines Agency website http://www.ema.europa.eu.